Fujimoto S, Miyazaki M, Endoh F, Takahashi O, Okui K, Morimoto Y
Cancer. 1985 Nov 15;56(10):2404-10. doi: 10.1002/1097-0142(19851115)56:10<2404::aid-cncr2820561011>3.0.co;2-c.
Thirty-two patients with inoperable hepatic cancer underwent intra-arterial hepatic infusion using mitomycin C (MMC) and 5-fluorouracil (5-FU) or intra-arterial hepatic chemoembolization using heated albumin microspheres containing MMC with an average diameter 45 +/- 8 micron. Nineteen of the 32 patients received the MMC microsphere treatment and another 13 received the conventional infusion treatment, lasting for 3.4 months. The administered doses of MMC microspheres were 11.7 +/- 11.1 mg as MMC in the 12 with metastatic cancer and 6.9 +/- 2.1 mg as MMC in the 7 with hepatocellular cancer (HCC). On the contrary, the 13 patients who underwent conventional infusion had average doses of MMC 34.5 +/- 17.3 mg and of 5-FU 13.4 +/- 7.7 g, over 3.4 months. An objective tumor response was obtained in 13/19 (68.4%) under MMC microsphere chemoembolization, compared to 6/13 (46.2%) under the conventional infusion. The average level of CEA in the 12 with metastatic cancer, who underwent MMC microsphere therapy, dropped from 57.7 ng/ml to 16.5 ng/ml, while that in the 10 patients on conventional infusion dropped from 24.0 ng/ml to 17.4 ng/ml; that of alpha-fetoprotein dropped in all 7 with HCC on MMC microsphere chemoembolization, compared to a fall in 1/3 on conventional infusion. With the MMC microsphere treatment, 5 patients from colorectal cancer lived for 15.6 +/- 7.6 months, 2 are alive with a long life expectancy; and 7 patients from gastric or pancreatic cancer lived for only 9.3 +/- 3.3 months. In case of conventional infusion, 6 patients from colorectal cancer survived for 8.6 +/- 3.2 months; and 4 patients from gastric or gallbladder cancer survived for 6.0 +/- 1.0 months. The MMC microsphere treatment is superior at P = 0.059 in survival duration to the conventional infusion treatment. However, much the same survival occurred in 7 on MMC microsphere chemoembolization and 3 on continuous infusion.
32例无法手术的肝癌患者接受了丝裂霉素C（MMC）和5-氟尿嘧啶（5-FU）的肝动脉灌注，或使用平均直径为45±8微米的含MMC的加热白蛋白微球进行肝动脉化疗栓塞。32例患者中，19例接受MMC微球治疗，另外13例接受传统灌注治疗，持续3.4个月。MMC微球的给药剂量在12例转移性癌患者中以MMC计为11.7±11.1mg，在7例肝细胞癌（HCC）患者中以MMC计为6.9±2.1mg。相反，13例接受传统灌注的患者在3.4个月内MMC平均剂量为34.5±17.3mg，5-FU平均剂量为13.4±7.7g。MMC微球化疗栓塞组13/19（68.4%）获得客观肿瘤反应，而传统灌注组为6/13（46.2%）。12例接受MMC微球治疗的转移性癌患者CEA平均水平从57.7ng/ml降至16.5ng/ml，而10例接受传统灌注的患者从24.0ng/ml降至17.4ng/ml；7例接受MMC微球化疗栓塞的HCC患者甲胎蛋白均下降，而传统灌注组仅1/3下降。接受MMC微球治疗的5例结直肠癌患者存活15.6±7.6个月，2例存活且预期寿命长；7例胃癌或胰腺癌患者仅存活9.3±3.3个月。传统灌注时，6例结直肠癌患者存活8.6±3.2个月；4例胃癌或胆囊癌患者存活6.0±1.0个月。MMC微球治疗在生存时间上优于传统灌注治疗，P=0.059。然而，7例接受MMC微球化疗栓塞的患者和3例持续灌注的患者生存情况大致相同。
